London-based start-up Entia is set to transform cancer treatment with its innovative at-home blood testing for patients. Securing an impressive £16 million in Series A funding, the company is ready to expand its remote patient monitoring system across the UK while pursuing regulatory approval in the US. This game-changing approach, co-led by BGF and Parkwalk, addresses the challenges of hospital outpatient appointments, offering cancer patients a more convenient and efficient way to monitor their health.
Entia's flagship device, Liberty, heralds a new era in cancer care by providing a remote, at-home solution for patients undergoing treatment. By empowering patients to monitor their health from the comfort of their homes, Entia eases the burden on healthcare providers, streamlining routine assessments and fostering a more proactive approach to healthcare.
CEO and founder of Entia, Dr. Toby Basey-Fisher, emphasizes the significance of patient-focused care beyond hospital walls. The shift towards remote monitoring benefits patients and proves highly advantageous for healthcare providers. This forward-thinking model enables early problem detection and intervention, prolonging treatment periods, reducing unplanned hospitalizations, and ultimately enhancing survival outcomes. Entia's visionary approach aligns with a preventative healthcare paradigm, promising a brighter future for cancer patients and the healthcare industry.
Entia's successful funding round signifies a groundbreaking advancement in cancer treatment, elevating patient care to new heights with its at-home blood testing and remote monitoring system. By embracing patient empowerment and proactive healthcare strategies, Entia takes a bold step towards revolutionizing cancer care and bringing a renewed sense of hope and efficiency to patients and healthcare providers alike.
